Researchers discover how SARS-CoV-2 infects and replicates in host cells
Posted: 9 November 2020 | Victoria Rees (Drug Target Review) | No comments yet
A team has revealed how SARS-CoV-2 infects cells, suggesting that targeting its RNA with drugs would stop the virus replicating.
Scientists have uncovered how the genome of SARS-CoV-2 – the coronavirus that causes COVID-19 – uses ‘genome origami’ to infect and replicate successfully inside host cells. The researchers say that this could inform the development of effective drugs that target specific parts of the virus genome, in the fight against COVID-19.
The study was conducted at the University of Cambridge, UK, in collaboration with Justus-Liebig University, Germany.
According to the researchers, all coronaviruses share the characteristic of having the largest single-stranded RNA genome in nature. This genome contains all the genetic code the virus needs to produce proteins, evade the immune system and replicate inside the human body. Much of that information is contained in the three-dimensional (3D) structure adopted by this RNA genome when it infects cells.
The researchers say most current work to find drugs and vaccines for COVID-19 is focused on targeting the proteins of the virus. As the shape of the RNA molecule is critical to its function, targeting the RNA directly with drugs to disrupt its structure would block the lifecycle and stop the virus replicating.
In the new study, the team uncovered the entire structure of the SARS-CoV-2 genome inside the host cell, revealing a network of RNA-RNA interactions spanning very long sections of the genome. Different functional parts along the genome need to work together despite the distance between them and the new structural data shows how this is accomplished to enable the coronavirus life cycle and cause disease.
“The RNA genome of coronaviruses is about three times bigger than an average viral RNA genome – it is huge,” said lead author Dr Omer Ziv at the University of Cambridge. “Researchers previously proposed that long-distance interactions along coronavirus genomes are critical for their replication and for producing the viral proteins, but until recently we did not have the right tools to map these interactions in full. Now that we understand this network of connectivity, we can start designing ways to target it effectively with therapeutics.”
In all cells the genome holds the code for the production of specific proteins, which are made when a molecular machine called a ribosome runs along the RNA reading the code until a ‘stop sign’ tells it to terminate. In coronaviruses, there is a special spot where the ribosome only stops 50 percent of the times in front of the stop sign. In the other half of cases, a unique RNA shape makes the ribosome jump over the stop sign and produce additional viral proteins. By mapping this RNA structure and the long-range interactions involved, the research uncovers the strategies by which coronaviruses produce their proteins to manipulate host cells.
“We show that interactions occur between sections of the SARS-CoV-2 RNA that are very long distances apart and we can monitor these interactions as they occur during early SARS-CoV-2 replication,” said Dr Lyudmila Shalamova, a co-lead investigator at Justus-Liebig University.
Dr Jon Price, at the Gurdon Institute and co-lead of the study, has developed a free, open-access interactive website hosting the entire RNA structure of SARS-CoV-2. This will enable researchers world-wide to use the new data in the development of drugs to target specific regions of the virus’s RNA genome.
The study was published in Molecular Cell.
Disease Research, Drug Targets, Genomics, RNAs, Structural Biology, Targets
Gurdon Institute, Justus-Liebig University, University of Cambridge
Dr Jon Price, Dr Lyudmila Shalamova, Dr Omer Ziv